Evidence map›Paper›PMID 35509827›Full record

ArticleJournal of ginseng research2022

Enzymatic bioconversion of ginseng powder increases the content of minor ginsenosides and potentiates immunostimulatory activity.

Jisang Park, Ju Kim, Eun-Sil Ko, Jong Hoon Jeong, Cheol-Oh Park, Jeong Hun Seo, Yong-Suk Jang

Abstract read
In one paragraph

Article in Journal of ginseng research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jisang ParkInnovative Research and Education Center for Integrated Bioactive Materials and the Department of Bioactive Material Sciences, Jeonbuk National University, Jeonju, Republic of Korea.
Ju KimDepartment of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju, Republic of Korea.
Eun-Sil KoR&D Center, General Bio Co., Ltd., Namwon, Republic of Korea.
Jong Hoon JeongR&D Center, General Bio Co., Ltd., Namwon, Republic of Korea.
Cheol-Oh ParkR&D Center, General Bio Co., Ltd., Namwon, Republic of Korea.
Jeong Hun SeoR&D Center, General Bio Co., Ltd., Namwon, Republic of Korea.
Yong-Suk JangInnovative Research and Education Center for Integrated Bioactive Materials and the Department of Bioactive Material Sciences, Jeonbuk National University, Jeonju, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ginsenosides are biologically active components of ginseng and have various functions. In this study, we investigated the immunomodulatory activity of a ginseng product generated from ginseng powder (GP) via enzymatic bioconversion. This product, General Bio compound K-10 mg solution (GBCK10S), exhibited increased levels of minor ginsenosides, including ginsenoside-F1, compound K, and compound Y. Methods: The immunomodulatory properties of GBCK10S were confirmed using mice and a human natural killer (NK) cell line. We monitored the expression of molecules involved in immune responses via enzyme-linked immunosorbent assay, flow cytometry, NK cell-targeted cell destruction, quantitative reverse-transcription real-time polymerase chain reaction, and Western blot analyses. Results: Oral administration of GBCK10S significantly increased serum immunoglobulin M levels and primed splenocytes to express pro-inflammatory cytokines such as interleukin-6, tumor necrosis factor-α, and interferon-γ. Oral administration of GBCK10S also activated NK cells in mice. Furthermore, GBCK10S treatment stimulated a human NK cell line Conclusion: GBCK10S may have potent immunostimulatory properties and can activate immune responses mediated by B cells, Th1-type T cells, and NK cells.

Indexed as

Ab, antibodyAPC, allophycocyaninBioconversionCK, compound KCO, compound OCon A, concanavalin ACY, compound YELISA, enzyme-linked immunosorbent assayFBS, fetal bovine serumFITC, fluorescein isothiocyanateGBCK10S, General Bio compound-K 10 mg solutionGinsengGinsenosideGP, ginseng powderGZMB, granzyme BHPLC, high performance liquid chromatographyIFN, interferonIg, immunoglobulinIL, interleukinLymphocyteNK cellsNK, natural killerOD, optical densityPBS, phosphate-buffered salinePE, phycoerythrinRT-PCR, reverse-transcription polymerase chain reactionSD, standard deviationSE, standard errorSTAT, signal transducer and activator of transcriptionTh, helper TTNF, tumor necrosis factor

Identifiers

PMID35509827
PMCPMC9058844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.